Please login to the form below

Not currently logged in
Email:
Password:

Clovis Oncology

This page shows the latest Clovis Oncology news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene raises $903m from Hong Kong IPO

China’s BeiGene raises $903m from Hong Kong IPO

It’s a potential rival to marketed PARP inhibitors from AstraZeneca (Lynparza), Clovis Oncology (Rubraca) and Tesaro (Zejula).

Latest news

  • Maintenance OK boosts AstraZeneca’s Lynparza in Europe Maintenance OK boosts AstraZeneca’s Lynparza in Europe

    The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for ... That is another key element in its defence of the brand, as is

  • Maintenance OK boosts AstraZeneca’s Lynparza in Europe Maintenance OK boosts AstraZeneca’s Lynparza in Europe

    The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for ... That is another key element in its defence of the brand, as is

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    It also gave its blessing to Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) for the treatment of relapsed or progressive ovarian cancer in patients who have already been treated with two

  • CHMP backs AZ’s Lynparza for ovarian cancer maintenance CHMP backs AZ’s Lynparza for ovarian cancer maintenance

    in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib). ... Tesaro and Clovis will report fourth quarter results this week.

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    Approval beyond ovarian cancer is a big hurdle cleared for Lynparza as it tries to keep pace in the market with newer PARP inhibitor entrants Rubraca (rucaparib) from Clovis Oncology and ... Merck (known as MSD outside the US and Canada) got involved in

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Latest appointments

  • Roche's Julie Warner joins Boyds Roche's Julie Warner joins Boyds

    She has previously held positions at Clovis Oncology UK, Genzyme and Gregory Fryer Associate, and was most recently senior regulatory programme manager at Roche.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics